Gadapuram T.K.,Guru nanak Institute of Pharmacy |
Murthy J.S.N.,Vignana Bharathi Institute of Technology |
Rajannagari R.R.,Malla Reddy Pharmacy College |
Kandati V.,Malla Reddy Pharmacy College |
Shukla R.,Amity University
Journal of Basic and Clinical Physiology and Pharmacology | Year: 2013
Background: Cocculus hirsutus, commonly known as broom creeper, belongs to the family Menispermaceae. It is widely used in folk medicine to treat leprosy, skin diseases, dyspepsia, etc. Hence, an effort has been made to investigate the nephroprotective potential of C. hirsutus. Methods: The nephroprotective activity of ethanolic C. hirsutus leaf extract (ECHE) in the 5/6 nephrectomized rat model was investigated. Different parameters like postoperative survival rate, change in body weight and levels of red blood corpuscles (RBCs), hemoglobin (Hb), triglyceride, cholesterol, creatinine, urea and uric acid were estimated in experimental rats. Results: The findings revealed the postoperative survival rate of rats in the investigated novel method to be 100%. Change in the body weight of ECHE-treated groups I and II was found to be 32 and 30 g, respectively. These values suggested that ECHE treatment normalized the elevated body weight levels in experimental rats. Furthermore, ECHE treatment normalized the decreased RBC levels and the elevated Hb, triglyceride, cholesterol, creatinine, urea and uric acid levels in experimental rats. Conclusions: The results indicate that C. hirsutus has strong nephroprotective activity. However, further scrutiny is essential for isolation and characterization of the active components that can be employed to allay various human maladies.
Das A.K.,Malla Reddy Pharmacy College |
Srilakshmi N.,Malla Reddy Pharmacy College |
Pandit P.,Malla Reddy Pharmacy College
International Journal of Research in Ayurveda and Pharmacy | Year: 2013
Although the drug delivery system has been changing with time, the conventional tablet preparation is still dominating in dosage form preparation. Conventional tablet has more advantages than the other formulations such as low cost of manufacture, package, easier shipment, tamper proof and stablility for longer duration. Schizophrenia is a severe illness with substantial effects on individual and social functioning. First-line treatment in these patients is the use of atypical antipsychotics. The atypical antipsychotic Quetiapine was approved in 1997 by the US Food and Drug Administration (FDA), and has been available since 2007. The treatment of schizophrenia has changed considerably with the introduction of atypical antipsychotics. Quetiapine is among the most widely used atypical antipsychotics, and along with clozapine has the least propensity to induce extrapyramidal motor symptoms. It is thought that the drug's therapeutic activity in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) receptorantagonisms.The main objective of this work is to develop a pharmaceutical equivalent, stable, robust immediate release tablet. The tablets were prepared by using wet granulation method with sodium starch glycolate and micro crystalline cellulose used intra and extra granularly. The dosage form was prepared and evaluated based on various parameters such as bulk, tapped density, sieve analysis, drug uniformity, disintegration and dissolution etc.
Das A.K.,Malla Reddy Pharmacy College |
Bhanja S.,Malla Reddy Pharmacy College |
Srilakshmi N.,Malla Reddy Pharmacy College
Asian Journal of Pharmaceutical and Clinical Research | Year: 2013
The scenario of pharmaceutical drug delivery is rapidly challenging, but conventional pharmaceutical dosage forms are still dominating. Tablets formulations are mostly preferred because of low cost of manufacture, package, shipment, increased stability and virtual tamper resistance. The main goal of this study was to develop a stable formulation of antipsychotics Quetiapine as an immediate-release tablet. Quetiapine has beneficial calming properties and successfully treats the symptoms of aggression, anxiety and hostility that can accompany acute exacerbations of schizophrenia. The atypical antipsychotic Quetiapine was approved in 1997 by the US Food and Drug Administration (FDA), for formulation. Furthermore, while current prescribing information recommends that Quetiapine can be administered at doses up to 750mg/day (800mg/day in the USA and Canada), there is growing evidence that dosing up to 1600mg/day of Quetiapine has been well tolerated in some patients. The task of developing immediate release tablet is accomplished by using a suitable diluent and super-disintegrants. Faster disintegration of the tablet administrated orally minimizes absorption time and improves its bioavailability in less time. The formulation development work was initiated with wet granulation. The granules were evaluated for angle of repose, bulk density, compressibility index, tapped density and Hausner ratio. The tablets for the formulations i.e.F1to F8 were subject to hardness, thickness, friability, weight variation test, drug content uniformity and in vitro disintegration time, in vitro drug release studies and stability studies. The granules showed satisfactory flow properties and good compressibility. all the tablet formulations i.e.F1 to F8 showed acceptable pharmacotechnical properties and complied with in-house specifications for tested parameters. From the all formulations, F8 was optimised and in vitro disintegration time and in vitro drug release studies were found to be 4.0 (min) and 98.5 % respectively. The optimized formulation is further selected and compared with the release profile of the innovator product and similarity factor was conducted. The result was found to be more than 50%.The optimized,formulation, F8 was conducted for stability studies according to ICH guideline. The results indicate that there were insignificant changes during studies. Hence, the results suggest the feasibility of developing immediate release tablets consisting of Quetiapine, which has an excellent tolerability profile offering high patient acceptability that may promote patient adherence to medication and an improved quality of life.